NewEdge Advisors LLC Has $33,000 Holdings in DaVita Inc. $DVA

Key Points

• NewEdge Advisors cut its DaVita stake by 96.9% in the first quarter, leaving 217 shares worth approximately $33,000. Institutional investors collectively own 90.12% of the company.
• Analyst sentiment is mixed, with four Buy, three Hold, and one Sell rating. DaVita has an average “Hold” rating and a consensus price target of $221.75.
• DaVita exceeded quarterly expectations, reporting $4.02 in EPS and $3.55 billion in revenue, up 5.2% year over year. Shares opened at $178.70, below their 50-day moving average of $212.49.

NewEdge Advisors LLC decreased its stake in DaVita Inc. (NYSE:DVA - Free Report) by 96.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217 shares of the company's stock after selling 6,686 shares during the quarter. NewEdge Advisors LLC's holdings in DaVita were worth $33,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of DVA. Root Financial Partners LLC lifted its holdings in shares of DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company's stock valued at $29,000 after acquiring an additional 105 shares during the period. Caitlin John LLC bought a new stake in shares of DaVita in the 4th quarter worth about $34,000. Sankala Group LLC acquired a new stake in shares of DaVita during the 4th quarter worth about $39,000. Canada Pension Plan Investment Board bought a new position in DaVita during the 2nd quarter valued at about $43,000. Finally, Kestra Advisory Services LLC acquired a new position in DaVita in the fourth quarter valued at about $45,000. 90.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $265.00 price objective on shares of DaVita in a report on Wednesday, August 5th. Raymond James Financial set a $220.00 price target on DaVita in a report on Friday, August 7th. Barclays increased their target price on DaVita from $218.00 to $224.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 5th. Zacks Research cut DaVita from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. Finally, UBS Group upped their price target on shares of DaVita from $235.00 to $270.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $221.75.

Insider Buying and Selling at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the business's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company's stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.90% of the stock is currently owned by company insiders.

DaVita Stock Down 0.7%

Shares of DVA opened at $178.70 on Friday. The stock's fifty day simple moving average is $212.49 and its 200-day simple moving average is $183.06. The firm has a market capitalization of $11.40 billion, a PE ratio of 14.62, a price-to-earnings-growth ratio of 0.60 and a beta of 0.88. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping analysts' consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same period last year, the company earned $2.95 earnings per share. The company's revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.

DaVita Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source